The effects of Peroxisome Proliferator-Activated Receptor-γ agonist on a murine model of experimental allergic rhinitis

PPAR-γ activation with rosiglitazone effectively inhibited allergic symptom development, nasal mucosal inflammation, and production of ovoalbumin-specific immunoglobulin E and Th2-type cytokine. Our results provide evidence of the therapeutic potential of PPAR-γ agonist for the treatment of allergic rhinitis.